骨肉瘤患者SLCO1B1基因多态性与大剂量甲氨蝶呤不良反应的相关性

Correlation of SLCO1B1 gene polymorphism with adverse reactions of high-dose methotrexate in osteosarcoma patients

目的探讨SCLO1B1基因多态性与大剂量甲氨蝶呤(HD-MTX)化疗不良反应的相关性。方法回顾性收集HD-MTX化疗联合亚叶酸钙解救的骨肉瘤患者96例,采用实时荧光定量PCR法检测基因型,并分析基因型对各主要不良反应发生的影响。结果 SLCO1B1 rs 11045879 TT型和rs 4149081 GG型的骨肉瘤患者,其HD-MTX化疗后发生恶心呕吐、肝功能损害和肾功能损害的风险明显增加,而与骨髓抑制、口腔黏膜炎不相关。结论 SLCO1B1基因型与HD-MTX不良反应相关。

AIM To investigate the relationship between SCLO1B1 gene polymorphism and adverse reactions of high-dose methotrexate(HD-MTX) chemotherapy. METHODS Totally 96 osteosarcoma patients treated with HD-MTX and calcium subfolate were collected. The real time fluorescence quantitative PCR was used to detect the genotypes of SLCO1B1, and the effects on the major adverse reactions were analyzed by then. RESULTS Individuals with SLCO1B1 rs 11045879 TT genotype or rs 4149081 GG genotypes showed a significantly increased incidence of nausea and vomiting, liver function damage and renal function damage, but it was not related to myelosuppression and oral mucositis. CONCLUSION SLCO1B1 genotypes are associated with adverse effects of HD-MTX.